Local News

Inspire Signs Drug Development Deal With German Firm

Posted February 21, 2006

— Inspire Pharmaceuticals

will seek to develop a new product for the treatment of rhinitis under a licensing agreement with pharmaceutical firm Boehringer Ingelheim International GmbH, which is based in Germany.

Rhinitis is one of the most common forms of allergic conditions.

Inspire wants to develop an intranasal dosage form of epinastine, the active drug substance it is licensing. Inspire said it wants to begin testing of the drug later this year.

Terms of the deal were not disclosed.

Inspire paid Boehringer Ingelheim an upfront license fee, will fund development efforts, and pay royalties if the drug is approved. The agreement covers Canada and the United States.


Please with your WRAL.com account to comment on this story. You also will need a Facebook account to comment.

Oldest First
View all